These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29176511)

  • 21. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017.
    Huskamp HA; Riedel LE; Barry CL; Busch AB
    Med Care; 2018 Jun; 56(6):505-509. PubMed ID: 29668645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.
    Chetty M; Kenworthy JJ; Langham S; Walker A; Dunlop WC
    Addict Sci Clin Pract; 2017 Feb; 12(1):6. PubMed ID: 28235415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Availability of addiction medications in private health plans.
    Horgan CM; Reif S; Hodgkin D; Garnick DW; Merrick EL
    J Subst Abuse Treat; 2008 Mar; 34(2):147-56. PubMed ID: 17499959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vermont responds to its opioid crisis.
    Simpatico TA
    Prev Med; 2015 Nov; 80():10-1. PubMed ID: 25869219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorder.
    Velez FF; Colman S; Kauffman L; Anastassopoulos K; Murphy S; Maricich Y
    Hosp Pract (1995); 2021 Dec; 49(5):341-347. PubMed ID: 34275401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.
    Van Zee A; Fiellin DA
    Am J Public Health; 2019 Mar; 109(3):393-394. PubMed ID: 30726142
    [No Abstract]   [Full Text] [Related]  

  • 31. Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.
    Knudsen HK; Lofwall MR; Walsh SL; Havens JR; Studts JL
    J Addict Med; 2018; 12(1):31-39. PubMed ID: 28914663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost and utilization outcomes of opioid-dependence treatments.
    Baser O; Chalk M; Fiellin DA; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-03.
    de Wet CJ; Reed LJ; Bearn J
    Addiction; 2005 Apr; 100(4):495-9. PubMed ID: 15784064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.
    Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH
    Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.
    Toce MS; Chai PR; Burns MM; Boyer EW
    J Med Toxicol; 2018 Dec; 14(4):306-322. PubMed ID: 30377951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Financial factors and the implementation of medications for treating opioid use disorders.
    Knudsen HK; Roman PM
    J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.